PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Bastien, Roy Rl ^a   Rodríguez Lescure, Álvaro ^b   Ebbert, Mark Tw ^a   Prat, Aleix ^c,d   Munárriz, Blanca ^e   Rowe, Leslie ^a   Miller, Patricia ^a   Ruiz Borrego, Manuel ^f   Anderson, Daniel ^a   Lyons, Bradley ^a   Álvarez, Isabel ^g   Dowell, Tracy ^a   Wall, David ^a   Seguí, Miguel Ángel ^h   Barley, Lee ^a   Boucher, Kenneth M ⁱ   Alba, Emilio ^j   Pappas, Lisa ⁱ   Davis, Carole A ^k   Aranda, Ignacio ^l   Fauron, Christiane ^a   Stijleman, Inge J ^k   Palacios, José ^f   Antán, Antonio ^m   Carrasco, Eva ⁿ   Caballero, Rosalía ⁿ   Ellis, Matthew J ^o   Nielsen, Torsten O ^p   Perou, Charles M ^c   Astill, Mark ^a   Bernard, Philip S ^a,i,k   Martín, Miguel ^q   more..

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h Corporati Sanitaria Parc Taulí ^*  (Spain)

ⁱ UNIVERSITY OF UTAH   (United States)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^k UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^l HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^m HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁿ GEICAM   (Spain)

^o WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^q HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL PROLIFERATION; ERBB2 GENE; ESR1 GENE; FEMALE; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; PAM50 GENE; PGR GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CLUSTER ANALYSIS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIMIT OF DETECTION; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866888703     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-44     Document Type: Article

References (39)

1. Molecular portraits of human breast tumours. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Nature 2000 406 6797 747 752 10.1038/35021093 10963602
2. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Proc Natl Acad Sci U S A 2001 98 19 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
3. Supervised risk predictor of breast cancer based on intrinsic subtypes. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. J Clin Oncol 2009 27 8 1160 1167 10.1200/JCO.2008.18.1370 19204204
4. The molecular portraits of breast tumors are conserved across microarray platforms. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al. BMC Genomics 2006 7 96 10.1186/1471-2164-7-96 16643655 (Pubitemid 43786485)
5. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, et al. Clin Cancer Res 2010 16 21 5222 5232 10.1158/1078-0432.CCR-10-1282 20837693
6. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Cheang MCU, Voduc KD, Dongsheng T, Jiang S, Leung S, Chia SK, Shepherd L, Levine MN, Pritchard KI, Davies SR, et al. Clin Cancer Res in press
7. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Tibshirani R, Hastie T, Narasimhan B, Chu G, Proc Natl Acad Sci U S A 2002 99 10 6567 6572 10.1073/pnas.082099299 12011421 (Pubitemid 34526173)
8. Repeated observation of breast tumor subtypes in independent gene expression data sets. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Proc Natl Acad Sci U S A 2003 100 14 8418 8423 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
9. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z103. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, et al. J Clin Oncol 2011 29 17 2342 2349 10.1200/JCO.2010.31.6950 21555689
10. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, et al. Breast Cancer Res Treat 2012 132 3 1049 1062 10.1007/s10549-011-1895-2 22198468
11. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L, Clin Cancer Res 2012 18 4 1109 1119 10.1158/1078-0432.CCR-11-2762 22235097
12. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, et al. J Clin Oncol 2012 30 7 729 734 10.1200/JCO.2011.36.2574 22291085
13. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. N Engl J Med 2004 351 27 2817 2826 10.1056/NEJMoa041588 15591335 (Pubitemid 40051905)
14. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, et al. BMC Cancer 2008 8 339 10.1186/1471-2407-8-339 19025599
15. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. J Natl Cancer Inst 2006 98 4 262 272 10.1093/jnci/djj052 16478745 (Pubitemid 43264710)
16. A gene-expression signature as a predictor of survival in breast cancer. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. N Engl J Med 2002 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
17. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, et al. Breast Cancer Res 2006 8 2 23 10.1186/bcr1399 16626501 (Pubitemid 44377908)
18. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Mullins M, Perreard L, Quackenbush JF, Gauthier N, Bayer S, Ellis M, Parker J, Perou CM, Szabo A, Bernard PS, Clin Chem 2007 53 7 1273 1279 10.1373/clinchem.2006.083725 17525107 (Pubitemid 47020983)
19. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Clin Cancer Res 2004 10 16 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 (Pubitemid 39100473)
20. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Morrison DH, Rahardja D, King E, Peng Y, Sarode VR, Br J Cancer 2012
21. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, et al. Breast Cancer Res 2012 14 3 83 10.1186/bcr3198 22621334
22. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E, et al. J Natl Cancer Inst 2008 100 11 805 814 10.1093/jnci/djn151 18505968 (Pubitemid 351809668)
23. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Allred DC, Harvey JM, Berardo M, Clark GM, Modern Pathol 1998 11 2 155 168 (Pubitemid 28144151)
24. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. J Clin Oncol 2007 25 1 118 145 17159189 (Pubitemid 350003059)
25. Cluster analysis and display of genome-wide expression patterns. Eisen MB, Spellman PT, Brown PO, Botstein D, Proc Natl Acad Sci U S A 1998 95 25 14863 14868 10.1073/pnas.95.25.14863 9843981 (Pubitemid 29003722)
26. Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. Ebbert MT, Bastien RR, Boucher KM, Martin M, Carrasco E, Caballero R, Stijleman IJ, Bernard PS, Facelli JC, J Clin Bioinforma 2011 1 37 10.1186/2043-9113-1-37 22196354
27. Statistical Significance of Clustering for High-Dimension, Low-Sample Size Data. Liu Y, Hayes DN, Nobel A, Marron JS, J Am Stat Assoc 2008 103 483 1281 1293 10.1198/016214508000000454
28. Systematic Bias in Genomic Classification Due to Contaminating Non-neoplastic Tissue in Breast Tumor Samples. Elloumi F, Hu Z, Li Y, Parker JS, Gulley ML, Amos KD, Troester MA, BMC Med Genomics 2011 4 54 10.1186/1755-8794-4-54 21718502
29. Direct multiplexed measurement of gene expression with color-coded probe pairs. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, et al. Nat Biotechnol 2008 26 3 317 325 10.1038/nbt1385 18278033 (Pubitemid 351355126)
30. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, et al. Clin Cancer Res 2012 18 16 4465 4472 10.1158/1078-0432.CCR-12-0286 22711706
31. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, et al. Clin Cancer Res 2012 18 8 2402 2412 10.1158/1078-0432.CCR-11-2956 22351696
32. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. Soreide K, J Clin Pathol 2009 62 1 1 5 10.1136/jcp.2008.061010 18818262
33. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. J Clin Oncol 2010 28 16 2784 2795 10.1200/JCO.2009.25.6529 20404251
34. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Garcia-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J, Histopathology 2010 56 4 472 480 10.1111/j.1365-2559.2010. 03503.x 20459554
35. High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R, J Clin Oncol 2011 29 32 4279 4285 10.1200/JCO.2011.34.7963 21990395
36. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, et al. N Engl J Med 2010 362 22 2053 2065 10.1056/NEJMoa0909638 20519679
37. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM, Breast Cancer Res 2010 12 5 68 10.1186/bcr2635 20813035
38. Integrative analysis of genome-wide loss of heterozygosity and mono-allelic expression at nucleotide resolution reveals disrupted pathways in triple negative breast cancer. Ha G, Roth A, Lai D, Bashashati A, Ding J, Goya R, Giuliany R, Rosner J, Oloumi A, Shumansky K, et al. Genome Res 2012 Epub
39. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. Nature 2012 486 7403 346 352 22522925